nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lacosamide—Bortezomib—hematologic cancer	0.234	0.33	CrCrCtD
Lisdexamfetamine—Aspartame—Bortezomib—hematologic cancer	0.234	0.33	CrCrCtD
Lisdexamfetamine—Phenacemide—Vorinostat—hematologic cancer	0.187	0.263	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Melphalan—hematologic cancer	0.0548	0.0773	CrCrCtD
Lisdexamfetamine—SLC18A2—hematopoietic system—hematologic cancer	0.000529	0.161	CbGeAlD
Lisdexamfetamine—SLC6A3—hematopoietic system—hematologic cancer	0.0004	0.122	CbGeAlD
Lisdexamfetamine—SLC18A2—blood—hematologic cancer	0.00035	0.107	CbGeAlD
Lisdexamfetamine—SLC18A2—lung—hematologic cancer	0.000307	0.0938	CbGeAlD
Lisdexamfetamine—SLC18A2—testis—hematologic cancer	0.00029	0.0885	CbGeAlD
Lisdexamfetamine—SLC6A2—gonad—hematologic cancer	0.000245	0.0749	CbGeAlD
Lisdexamfetamine—SLC6A3—lung—hematologic cancer	0.000232	0.0709	CbGeAlD
Lisdexamfetamine—SLC6A3—testis—hematologic cancer	0.000219	0.0669	CbGeAlD
Lisdexamfetamine—SLC18A2—lymph node—hematologic cancer	0.00021	0.0641	CbGeAlD
Lisdexamfetamine—SLC6A2—lung—hematologic cancer	0.000187	0.0572	CbGeAlD
Lisdexamfetamine—SLC6A2—testis—hematologic cancer	0.000177	0.054	CbGeAlD
Lisdexamfetamine—SLC6A2—lymph node—hematologic cancer	0.000128	0.0391	CbGeAlD
Lisdexamfetamine—Lacosamide—CA9—hematologic cancer	0.0001	0.614	CrCbGaD
Lisdexamfetamine—Vomiting—Ifosfamide—hematologic cancer	6.63e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Cisplatin—hematologic cancer	6.62e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Tachycardia—Dexamethasone—hematologic cancer	6.61e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Tachycardia—Betamethasone—hematologic cancer	6.61e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Headache—Alitretinoin—hematologic cancer	6.61e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—hematologic cancer	6.61e-05	0.000267	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—hematologic cancer	6.6e-05	0.000267	CcSEcCtD
Lisdexamfetamine—Nausea—Thalidomide—hematologic cancer	6.58e-05	0.000267	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Triamcinolone—hematologic cancer	6.57e-05	0.000266	CcSEcCtD
Lisdexamfetamine—Rash—Ifosfamide—hematologic cancer	6.57e-05	0.000266	CcSEcCtD
Lisdexamfetamine—Dermatitis—Ifosfamide—hematologic cancer	6.57e-05	0.000266	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—hematologic cancer	6.56e-05	0.000266	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Dexamethasone—hematologic cancer	6.55e-05	0.000265	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Betamethasone—hematologic cancer	6.55e-05	0.000265	CcSEcCtD
Lisdexamfetamine—Dizziness—Irinotecan—hematologic cancer	6.54e-05	0.000265	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—hematologic cancer	6.54e-05	0.000265	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—hematologic cancer	6.51e-05	0.000264	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—hematologic cancer	6.49e-05	0.000263	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—hematologic cancer	6.49e-05	0.000263	CcSEcCtD
Lisdexamfetamine—Vomiting—Vincristine—hematologic cancer	6.46e-05	0.000262	CcSEcCtD
Lisdexamfetamine—Anorexia—Dexamethasone—hematologic cancer	6.46e-05	0.000262	CcSEcCtD
Lisdexamfetamine—Anorexia—Betamethasone—hematologic cancer	6.46e-05	0.000262	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisolone—hematologic cancer	6.45e-05	0.000261	CcSEcCtD
Lisdexamfetamine—Asthenia—Cisplatin—hematologic cancer	6.45e-05	0.000261	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—hematologic cancer	6.44e-05	0.000261	CcSEcCtD
Lisdexamfetamine—Fatigue—Triamcinolone—hematologic cancer	6.44e-05	0.000261	CcSEcCtD
Lisdexamfetamine—Rash—Vincristine—hematologic cancer	6.41e-05	0.000259	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vincristine—hematologic cancer	6.4e-05	0.000259	CcSEcCtD
Lisdexamfetamine—Headache—Vincristine—hematologic cancer	6.37e-05	0.000258	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.33e-05	0.000256	CcSEcCtD
Lisdexamfetamine—Nausea—Carmustine—hematologic cancer	6.32e-05	0.000256	CcSEcCtD
Lisdexamfetamine—Vomiting—Mitoxantrone—hematologic cancer	6.29e-05	0.000255	CcSEcCtD
Lisdexamfetamine—Vomiting—Irinotecan—hematologic cancer	6.29e-05	0.000255	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—hematologic cancer	6.27e-05	0.000254	CcSEcCtD
Lisdexamfetamine—Nausea—Alitretinoin—hematologic cancer	6.26e-05	0.000254	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—hematologic cancer	6.26e-05	0.000254	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—hematologic cancer	6.26e-05	0.000253	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—hematologic cancer	6.25e-05	0.000253	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—hematologic cancer	6.24e-05	0.000253	CcSEcCtD
Lisdexamfetamine—Rash—Irinotecan—hematologic cancer	6.24e-05	0.000253	CcSEcCtD
Lisdexamfetamine—Rash—Mitoxantrone—hematologic cancer	6.24e-05	0.000253	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irinotecan—hematologic cancer	6.23e-05	0.000252	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mitoxantrone—hematologic cancer	6.23e-05	0.000252	CcSEcCtD
Lisdexamfetamine—Headache—Mitoxantrone—hematologic cancer	6.2e-05	0.000251	CcSEcCtD
Lisdexamfetamine—Headache—Irinotecan—hematologic cancer	6.2e-05	0.000251	CcSEcCtD
Lisdexamfetamine—Nausea—Ifosfamide—hematologic cancer	6.19e-05	0.000251	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Cisplatin—hematologic cancer	6.15e-05	0.000249	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—hematologic cancer	6.14e-05	0.000249	CcSEcCtD
Lisdexamfetamine—Anxiety—Prednisone—hematologic cancer	6.13e-05	0.000248	CcSEcCtD
Lisdexamfetamine—Vomiting—Gemcitabine—hematologic cancer	6.13e-05	0.000248	CcSEcCtD
Lisdexamfetamine—Insomnia—Betamethasone—hematologic cancer	6.13e-05	0.000248	CcSEcCtD
Lisdexamfetamine—Insomnia—Dexamethasone—hematologic cancer	6.13e-05	0.000248	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.11e-05	0.000248	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—hematologic cancer	6.08e-05	0.000246	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—hematologic cancer	6.08e-05	0.000246	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—hematologic cancer	6.07e-05	0.000246	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—hematologic cancer	6.07e-05	0.000246	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—hematologic cancer	6.06e-05	0.000246	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—hematologic cancer	6.04e-05	0.000245	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—hematologic cancer	6.04e-05	0.000245	CcSEcCtD
Lisdexamfetamine—Nausea—Vincristine—hematologic cancer	6.04e-05	0.000244	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—hematologic cancer	6.03e-05	0.000244	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—hematologic cancer	6.01e-05	0.000243	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisolone—hematologic cancer	5.98e-05	0.000242	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Dexamethasone—hematologic cancer	5.96e-05	0.000241	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Betamethasone—hematologic cancer	5.96e-05	0.000241	CcSEcCtD
Lisdexamfetamine—Urticaria—Triamcinolone—hematologic cancer	5.93e-05	0.00024	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—hematologic cancer	5.91e-05	0.000239	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Triamcinolone—hematologic cancer	5.9e-05	0.000239	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—hematologic cancer	5.9e-05	0.000239	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Betamethasone—hematologic cancer	5.89e-05	0.000238	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dexamethasone—hematologic cancer	5.89e-05	0.000238	CcSEcCtD
Lisdexamfetamine—Nausea—Mitoxantrone—hematologic cancer	5.88e-05	0.000238	CcSEcCtD
Lisdexamfetamine—Nausea—Irinotecan—hematologic cancer	5.88e-05	0.000238	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—hematologic cancer	5.87e-05	0.000238	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—hematologic cancer	5.85e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.85e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.85e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Fatigue—Dexamethasone—hematologic cancer	5.84e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Fatigue—Betamethasone—hematologic cancer	5.84e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—hematologic cancer	5.79e-05	0.000235	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—hematologic cancer	5.79e-05	0.000234	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisone—hematologic cancer	5.76e-05	0.000233	CcSEcCtD
Lisdexamfetamine—Skin disorder—Prednisone—hematologic cancer	5.73e-05	0.000232	CcSEcCtD
Lisdexamfetamine—Nausea—Gemcitabine—hematologic cancer	5.73e-05	0.000232	CcSEcCtD
Lisdexamfetamine—Vomiting—Cisplatin—hematologic cancer	5.71e-05	0.000231	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—hematologic cancer	5.7e-05	0.000231	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—hematologic cancer	5.69e-05	0.000231	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—hematologic cancer	5.69e-05	0.00023	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—hematologic cancer	5.68e-05	0.00023	CcSEcCtD
Lisdexamfetamine—Rash—Cisplatin—hematologic cancer	5.67e-05	0.000229	CcSEcCtD
Lisdexamfetamine—Dermatitis—Cisplatin—hematologic cancer	5.66e-05	0.000229	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—hematologic cancer	5.65e-05	0.000229	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—hematologic cancer	5.63e-05	0.000228	CcSEcCtD
Lisdexamfetamine—Anorexia—Prednisone—hematologic cancer	5.62e-05	0.000228	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—hematologic cancer	5.62e-05	0.000227	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—hematologic cancer	5.58e-05	0.000226	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Triamcinolone—hematologic cancer	5.5e-05	0.000223	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—hematologic cancer	5.49e-05	0.000222	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—hematologic cancer	5.44e-05	0.00022	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—hematologic cancer	5.43e-05	0.00022	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—hematologic cancer	5.42e-05	0.000219	CcSEcCtD
Lisdexamfetamine—Urticaria—Dexamethasone—hematologic cancer	5.38e-05	0.000218	CcSEcCtD
Lisdexamfetamine—Urticaria—Betamethasone—hematologic cancer	5.38e-05	0.000218	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisolone—hematologic cancer	5.37e-05	0.000217	CcSEcCtD
Lisdexamfetamine—Asthenia—Triamcinolone—hematologic cancer	5.36e-05	0.000217	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Betamethasone—hematologic cancer	5.36e-05	0.000217	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dexamethasone—hematologic cancer	5.36e-05	0.000217	CcSEcCtD
Lisdexamfetamine—Nausea—Cisplatin—hematologic cancer	5.34e-05	0.000216	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—hematologic cancer	5.34e-05	0.000216	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—hematologic cancer	5.33e-05	0.000216	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—hematologic cancer	5.26e-05	0.000213	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—hematologic cancer	5.23e-05	0.000212	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—hematologic cancer	5.23e-05	0.000212	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—hematologic cancer	5.23e-05	0.000212	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—hematologic cancer	5.2e-05	0.00021	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Prednisone—hematologic cancer	5.19e-05	0.00021	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—hematologic cancer	5.19e-05	0.00021	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—hematologic cancer	5.19e-05	0.00021	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—hematologic cancer	5.16e-05	0.000209	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—hematologic cancer	5.13e-05	0.000208	CcSEcCtD
Lisdexamfetamine—Rash—Prednisolone—hematologic cancer	5.12e-05	0.000207	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisolone—hematologic cancer	5.11e-05	0.000207	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.11e-05	0.000207	CcSEcCtD
Lisdexamfetamine—Fatigue—Prednisone—hematologic cancer	5.09e-05	0.000206	CcSEcCtD
Lisdexamfetamine—Headache—Prednisolone—hematologic cancer	5.09e-05	0.000206	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—hematologic cancer	5.08e-05	0.000206	CcSEcCtD
Lisdexamfetamine—Constipation—Prednisone—hematologic cancer	5.05e-05	0.000204	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—hematologic cancer	5e-05	0.000202	CcSEcCtD
Lisdexamfetamine—Dizziness—Triamcinolone—hematologic cancer	4.94e-05	0.0002	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—hematologic cancer	4.93e-05	0.0002	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—hematologic cancer	4.93e-05	0.0002	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—hematologic cancer	4.9e-05	0.000198	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—hematologic cancer	4.89e-05	0.000198	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—hematologic cancer	4.88e-05	0.000198	CcSEcCtD
Lisdexamfetamine—Asthenia—Betamethasone—hematologic cancer	4.86e-05	0.000197	CcSEcCtD
Lisdexamfetamine—Asthenia—Dexamethasone—hematologic cancer	4.86e-05	0.000197	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—hematologic cancer	4.84e-05	0.000196	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisolone—hematologic cancer	4.82e-05	0.000195	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—hematologic cancer	4.81e-05	0.000195	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—hematologic cancer	4.8e-05	0.000194	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—hematologic cancer	4.79e-05	0.000194	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.78e-05	0.000194	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—hematologic cancer	4.77e-05	0.000193	CcSEcCtD
Lisdexamfetamine—Vomiting—Triamcinolone—hematologic cancer	4.75e-05	0.000192	CcSEcCtD
Lisdexamfetamine—Rash—Triamcinolone—hematologic cancer	4.71e-05	0.000191	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—hematologic cancer	4.71e-05	0.000191	CcSEcCtD
Lisdexamfetamine—Dermatitis—Triamcinolone—hematologic cancer	4.7e-05	0.00019	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—hematologic cancer	4.7e-05	0.00019	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—hematologic cancer	4.69e-05	0.00019	CcSEcCtD
Lisdexamfetamine—Headache—Triamcinolone—hematologic cancer	4.68e-05	0.000189	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—hematologic cancer	4.66e-05	0.000189	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dexamethasone—hematologic cancer	4.64e-05	0.000188	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Betamethasone—hematologic cancer	4.64e-05	0.000188	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—hematologic cancer	4.62e-05	0.000187	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—hematologic cancer	4.61e-05	0.000187	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—hematologic cancer	4.53e-05	0.000184	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—hematologic cancer	4.53e-05	0.000183	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—hematologic cancer	4.52e-05	0.000183	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—hematologic cancer	4.5e-05	0.000182	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—hematologic cancer	4.48e-05	0.000182	CcSEcCtD
Lisdexamfetamine—Dizziness—Betamethasone—hematologic cancer	4.48e-05	0.000181	CcSEcCtD
Lisdexamfetamine—Dizziness—Dexamethasone—hematologic cancer	4.48e-05	0.000181	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—hematologic cancer	4.46e-05	0.000181	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—hematologic cancer	4.46e-05	0.000181	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—hematologic cancer	4.44e-05	0.00018	CcSEcCtD
Lisdexamfetamine—Nausea—Triamcinolone—hematologic cancer	4.43e-05	0.00018	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.42e-05	0.000179	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—hematologic cancer	4.4e-05	0.000178	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—hematologic cancer	4.4e-05	0.000178	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—hematologic cancer	4.38e-05	0.000178	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—hematologic cancer	4.36e-05	0.000176	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisone—hematologic cancer	4.35e-05	0.000176	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—hematologic cancer	4.34e-05	0.000176	CcSEcCtD
Lisdexamfetamine—Vomiting—Betamethasone—hematologic cancer	4.31e-05	0.000174	CcSEcCtD
Lisdexamfetamine—Vomiting—Dexamethasone—hematologic cancer	4.31e-05	0.000174	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—hematologic cancer	4.29e-05	0.000174	CcSEcCtD
Lisdexamfetamine—Rash—Dexamethasone—hematologic cancer	4.27e-05	0.000173	CcSEcCtD
Lisdexamfetamine—Rash—Betamethasone—hematologic cancer	4.27e-05	0.000173	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—hematologic cancer	4.27e-05	0.000173	CcSEcCtD
Lisdexamfetamine—Dermatitis—Dexamethasone—hematologic cancer	4.27e-05	0.000173	CcSEcCtD
Lisdexamfetamine—Dermatitis—Betamethasone—hematologic cancer	4.27e-05	0.000173	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.26e-05	0.000172	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—hematologic cancer	4.25e-05	0.000172	CcSEcCtD
Lisdexamfetamine—Headache—Betamethasone—hematologic cancer	4.24e-05	0.000172	CcSEcCtD
Lisdexamfetamine—Headache—Dexamethasone—hematologic cancer	4.24e-05	0.000172	CcSEcCtD
Lisdexamfetamine—Asthenia—Prednisone—hematologic cancer	4.23e-05	0.000171	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—hematologic cancer	4.19e-05	0.00017	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—hematologic cancer	4.17e-05	0.000169	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—hematologic cancer	4.17e-05	0.000169	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—hematologic cancer	4.15e-05	0.000168	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—hematologic cancer	4.13e-05	0.000167	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—hematologic cancer	4.11e-05	0.000167	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—hematologic cancer	4.1e-05	0.000166	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—hematologic cancer	4.07e-05	0.000165	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—hematologic cancer	4.06e-05	0.000164	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Prednisone—hematologic cancer	4.04e-05	0.000163	CcSEcCtD
Lisdexamfetamine—Lisinopril—ABCB1—hematologic cancer	4.03e-05	0.248	CrCbGaD
Lisdexamfetamine—Nausea—Dexamethasone—hematologic cancer	4.02e-05	0.000163	CcSEcCtD
Lisdexamfetamine—Nausea—Betamethasone—hematologic cancer	4.02e-05	0.000163	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—hematologic cancer	4.01e-05	0.000162	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.98e-05	0.000161	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—hematologic cancer	3.98e-05	0.000161	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—hematologic cancer	3.95e-05	0.00016	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—hematologic cancer	3.92e-05	0.000159	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisone—hematologic cancer	3.9e-05	0.000158	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—hematologic cancer	3.9e-05	0.000158	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—hematologic cancer	3.86e-05	0.000156	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—hematologic cancer	3.81e-05	0.000946	CbGpPWpGaD
Lisdexamfetamine—Dyspnoea—Doxorubicin—hematologic cancer	3.81e-05	0.000154	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TFRC—hematologic cancer	3.8e-05	0.000945	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ARHGEF12—hematologic cancer	3.8e-05	0.000945	CbGpPWpGaD
Lisdexamfetamine—Somnolence—Doxorubicin—hematologic cancer	3.8e-05	0.000154	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCG2—hematologic cancer	3.78e-05	0.000939	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Doxorubicin—hematologic cancer	3.76e-05	0.000152	CcSEcCtD
Lisdexamfetamine—Vomiting—Prednisone—hematologic cancer	3.75e-05	0.000152	CcSEcCtD
Lisdexamfetamine—Rash—Prednisone—hematologic cancer	3.72e-05	0.000151	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—hematologic cancer	3.72e-05	0.000151	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—hematologic cancer	3.71e-05	0.00015	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ARHGEF1—hematologic cancer	3.7e-05	0.00092	CbGpPWpGaD
Lisdexamfetamine—Headache—Prednisone—hematologic cancer	3.7e-05	0.00015	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.69e-05	0.000149	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—hematologic cancer	3.68e-05	0.000915	CbGpPWpGaD
Lisdexamfetamine—Fatigue—Doxorubicin—hematologic cancer	3.68e-05	0.000149	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—hematologic cancer	3.67e-05	0.000148	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—hematologic cancer	3.65e-05	0.000148	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—hematologic cancer	3.65e-05	0.000148	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—hematologic cancer	3.63e-05	0.000147	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR5—hematologic cancer	3.59e-05	0.000892	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Methotrexate—hematologic cancer	3.54e-05	0.000143	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisone—hematologic cancer	3.5e-05	0.000142	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPEF1—hematologic cancer	3.49e-05	0.000866	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNA13—hematologic cancer	3.47e-05	0.000862	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—hematologic cancer	3.42e-05	0.000848	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TIAM1—hematologic cancer	3.41e-05	0.000848	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR4—hematologic cancer	3.4e-05	0.000845	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Epirubicin—hematologic cancer	3.4e-05	0.000138	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—hematologic cancer	3.39e-05	0.000137	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—hematologic cancer	3.38e-05	0.000137	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—hematologic cancer	3.37e-05	0.000137	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—hematologic cancer	3.37e-05	0.000837	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	3.34e-05	0.000829	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL17—hematologic cancer	3.32e-05	0.000826	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Epirubicin—hematologic cancer	3.31e-05	0.000134	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—JAK3—hematologic cancer	3.31e-05	0.000822	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—hematologic cancer	3.29e-05	0.000818	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—hematologic cancer	3.28e-05	0.000815	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR5—hematologic cancer	3.26e-05	0.00081	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Methotrexate—hematologic cancer	3.26e-05	0.000132	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—hematologic cancer	3.25e-05	0.000808	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	3.23e-05	0.000803	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—hematologic cancer	3.22e-05	0.000799	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	3.19e-05	0.000793	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR7—hematologic cancer	3.17e-05	0.000788	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL13—hematologic cancer	3.17e-05	0.000788	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Epirubicin—hematologic cancer	3.16e-05	0.000128	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	3.15e-05	0.000783	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3R1—hematologic cancer	3.15e-05	0.000783	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNA13—hematologic cancer	3.15e-05	0.000783	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—hematologic cancer	3.15e-05	0.000127	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—hematologic cancer	3.13e-05	0.000127	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—hematologic cancer	3.11e-05	0.000126	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—hematologic cancer	3.11e-05	0.000126	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TIAM1—hematologic cancer	3.1e-05	0.00077	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL3RA—hematologic cancer	3.09e-05	0.000768	CbGpPWpGaD
Lisdexamfetamine—Headache—Methotrexate—hematologic cancer	3.09e-05	0.000125	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—hematologic cancer	3.06e-05	0.000124	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—hematologic cancer	3.05e-05	0.000124	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—CREB1—hematologic cancer	3.01e-05	0.000748	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—JAK3—hematologic cancer	3.01e-05	0.000747	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	3e-05	0.000746	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—hematologic cancer	2.99e-05	0.000744	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RGS2—hematologic cancer	2.98e-05	0.000741	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—hematologic cancer	2.97e-05	0.000739	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRH—hematologic cancer	2.95e-05	0.000733	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRIO—hematologic cancer	2.95e-05	0.000733	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—hematologic cancer	2.93e-05	0.000119	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—hematologic cancer	2.93e-05	0.000119	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—hematologic cancer	2.92e-05	0.000118	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—hematologic cancer	2.92e-05	0.000724	CbGpPWpGaD
Lisdexamfetamine—Rash—Epirubicin—hematologic cancer	2.91e-05	0.000118	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—hematologic cancer	2.91e-05	0.000118	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—hematologic cancer	2.91e-05	0.000722	CbGpPWpGaD
Lisdexamfetamine—Headache—Epirubicin—hematologic cancer	2.89e-05	0.000117	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR7—hematologic cancer	2.88e-05	0.000716	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL13—hematologic cancer	2.88e-05	0.000716	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—LPAR1—hematologic cancer	2.86e-05	0.00071	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CYCS—hematologic cancer	2.83e-05	0.000703	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—hematologic cancer	2.82e-05	0.000114	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	2.82e-05	0.0007	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL3RA—hematologic cancer	2.81e-05	0.000698	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC11—hematologic cancer	2.76e-05	0.000684	CbGpPWpGaD
Lisdexamfetamine—Nausea—Epirubicin—hematologic cancer	2.74e-05	0.000111	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	2.74e-05	0.00068	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Doxorubicin—hematologic cancer	2.71e-05	0.00011	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RGS2—hematologic cancer	2.71e-05	0.000673	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—hematologic cancer	2.69e-05	0.000109	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—hematologic cancer	2.69e-05	0.000109	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRH—hematologic cancer	2.68e-05	0.000665	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRIO—hematologic cancer	2.68e-05	0.000665	CbGpPWpGaD
Lisdexamfetamine—Headache—Doxorubicin—hematologic cancer	2.67e-05	0.000108	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.66e-05	0.000662	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.65e-05	0.000657	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BCR—hematologic cancer	2.64e-05	0.000656	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDE4B—hematologic cancer	2.63e-05	0.000653	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR2—hematologic cancer	2.63e-05	0.000653	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—LPAR1—hematologic cancer	2.59e-05	0.000644	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RAC2—hematologic cancer	2.59e-05	0.000643	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—hematologic cancer	2.54e-05	0.000103	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—hematologic cancer	2.49e-05	0.000619	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—hematologic cancer	2.48e-05	0.000615	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADCY7—hematologic cancer	2.47e-05	0.000614	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC10—hematologic cancer	2.46e-05	0.00061	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDE4B—hematologic cancer	2.39e-05	0.000593	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR2—hematologic cancer	2.39e-05	0.000593	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.36e-05	0.000586	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAC2—hematologic cancer	2.35e-05	0.000584	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	2.34e-05	0.000582	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—hematologic cancer	2.29e-05	0.00057	CbGpPWpGaD
Lisdexamfetamine—Selegiline—ABCB1—hematologic cancer	2.26e-05	0.139	CrCbGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGEF12—hematologic cancer	2.25e-05	0.000558	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADCY7—hematologic cancer	2.24e-05	0.000558	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTHLH—hematologic cancer	2.24e-05	0.000555	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGEF1—hematologic cancer	2.19e-05	0.000544	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTGER4—hematologic cancer	2.18e-05	0.000541	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL3—hematologic cancer	2.05e-05	0.00051	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTHLH—hematologic cancer	2.03e-05	0.000504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	2.01e-05	0.000498	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTGER4—hematologic cancer	1.98e-05	0.000491	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL17—hematologic cancer	1.96e-05	0.000488	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGRN—hematologic cancer	1.96e-05	0.000488	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR5—hematologic cancer	1.93e-05	0.000479	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR4—hematologic cancer	1.92e-05	0.000478	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	1.92e-05	0.000477	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEF1—hematologic cancer	1.89e-05	0.00047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNA13—hematologic cancer	1.86e-05	0.000462	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL3—hematologic cancer	1.85e-05	0.000461	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TIAM1—hematologic cancer	1.83e-05	0.000455	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RASGRP1—hematologic cancer	1.79e-05	0.000445	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—hematologic cancer	1.78e-05	0.000443	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—hematologic cancer	1.78e-05	0.000443	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.78e-05	0.000442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAK3—hematologic cancer	1.78e-05	0.000441	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—hematologic cancer	1.77e-05	0.00044	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR4—hematologic cancer	1.75e-05	0.000434	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	1.73e-05	0.000429	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR7—hematologic cancer	1.7e-05	0.000423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL13—hematologic cancer	1.7e-05	0.000423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL3—hematologic cancer	1.68e-05	0.000418	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCOR2—hematologic cancer	1.68e-05	0.000417	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—hematologic cancer	1.67e-05	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL3RA—hematologic cancer	1.66e-05	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRKL—hematologic cancer	1.66e-05	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RASGRP1—hematologic cancer	1.63e-05	0.000404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRB2—hematologic cancer	1.61e-05	0.000401	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RGS2—hematologic cancer	1.6e-05	0.000398	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	1.59e-05	0.000394	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRH—hematologic cancer	1.58e-05	0.000393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRIO—hematologic cancer	1.58e-05	0.000393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CMA1—hematologic cancer	1.58e-05	0.000393	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.58e-05	0.000392	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGO2—hematologic cancer	1.55e-05	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPHK1—hematologic cancer	1.55e-05	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPAR1—hematologic cancer	1.53e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC9—hematologic cancer	1.53e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H3F3B—hematologic cancer	1.52e-05	0.000377	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—hematologic cancer	1.48e-05	0.000367	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	1.47e-05	0.000364	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRB2—hematologic cancer	1.46e-05	0.000364	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CSF2—hematologic cancer	1.44e-05	0.000358	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE4B—hematologic cancer	1.41e-05	0.00035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR2—hematologic cancer	1.41e-05	0.00035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	1.4e-05	0.000349	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF19—hematologic cancer	1.4e-05	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCG—hematologic cancer	1.39e-05	0.000345	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—JAK1—hematologic cancer	1.39e-05	0.000345	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAC2—hematologic cancer	1.39e-05	0.000345	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DKK1—hematologic cancer	1.38e-05	0.000342	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—hematologic cancer	1.37e-05	0.00034	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT5B—hematologic cancer	1.37e-05	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADCY7—hematologic cancer	1.33e-05	0.000329	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CSF2—hematologic cancer	1.31e-05	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2RA—hematologic cancer	1.3e-05	0.000323	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—XIAP—hematologic cancer	1.29e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—JAK1—hematologic cancer	1.26e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCG—hematologic cancer	1.26e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SH2B3—hematologic cancer	1.26e-05	0.000312	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMARCA4—hematologic cancer	1.26e-05	0.000312	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GZMB—hematologic cancer	1.25e-05	0.00031	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNA1—hematologic cancer	1.22e-05	0.000303	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EIF4EBP1—hematologic cancer	1.21e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSPB1—hematologic cancer	1.21e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL3—hematologic cancer	1.21e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SDC1—hematologic cancer	1.2e-05	0.000298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTHLH—hematologic cancer	1.2e-05	0.000298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2RA—hematologic cancer	1.18e-05	0.000293	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTGER4—hematologic cancer	1.17e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LCK—hematologic cancer	1.16e-05	0.000289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H3F3A—hematologic cancer	1.14e-05	0.000283	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCZ—hematologic cancer	1.11e-05	0.000275	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—hematologic cancer	1.08e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PARP1—hematologic cancer	1.07e-05	0.000266	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FBXW7—hematologic cancer	1.05e-05	0.000261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC2—hematologic cancer	1.03e-05	0.000256	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR4—hematologic cancer	1.03e-05	0.000256	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CBL—hematologic cancer	1e-05	0.00025	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL3—hematologic cancer	9.94e-06	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—hematologic cancer	9.82e-06	0.000244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN1—hematologic cancer	9.78e-06	0.000243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTPN11—hematologic cancer	9.65e-06	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RASGRP1—hematologic cancer	9.62e-06	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SYK—hematologic cancer	9.59e-06	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSP90AA1—hematologic cancer	9.59e-06	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—hematologic cancer	9.51e-06	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CREB1—hematologic cancer	9.35e-06	0.000232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT1—hematologic cancer	9.24e-06	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—hematologic cancer	9.15e-06	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6R—hematologic cancer	9.12e-06	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3R1—hematologic cancer	8.98e-06	0.000223	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—JAK2—hematologic cancer	8.73e-06	0.000217	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAP2K1—hematologic cancer	8.69e-06	0.000216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRB2—hematologic cancer	8.65e-06	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—hematologic cancer	8.64e-06	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFA—hematologic cancer	8.63e-06	0.000214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KITLG—hematologic cancer	8.5e-06	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT5A—hematologic cancer	8.31e-06	0.000207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—hematologic cancer	8.29e-06	0.000206	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—hematologic cancer	8.24e-06	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3R1—hematologic cancer	8.15e-06	0.000203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD86—hematologic cancer	7.97e-06	0.000198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—JAK2—hematologic cancer	7.93e-06	0.000197	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—hematologic cancer	7.86e-06	0.000195	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	7.82e-06	0.000194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	7.73e-06	0.000192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	7.73e-06	0.000192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	7.62e-06	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	7.61e-06	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	7.6e-06	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	7.53e-06	0.000187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	7.48e-06	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	7.46e-06	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	7.46e-06	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	6.97e-06	0.000173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	6.91e-06	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—hematologic cancer	6.89e-06	0.000171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	6.72e-06	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	6.57e-06	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	6.32e-06	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	6.26e-06	0.000155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	6.14e-06	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FN1—hematologic cancer	6.06e-06	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BAD—hematologic cancer	5.99e-06	0.000149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	5.99e-06	0.000149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	5.93e-06	0.000147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD80—hematologic cancer	5.81e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	5.8e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KIT—hematologic cancer	5.8e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	5.8e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	5.7e-06	0.000142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	5.56e-06	0.000138	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	5.52e-06	0.000137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	5.45e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	5.4e-06	0.000134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	5.39e-06	0.000134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	5.38e-06	0.000134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	5.14e-06	0.000128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	5.1e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	5.05e-06	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	4.99e-06	0.000124	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	4.88e-06	0.000121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	4.82e-06	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	4.68e-06	0.000116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	4.59e-06	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	4.57e-06	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	4.45e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	4.45e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	4.25e-06	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	4.17e-06	0.000104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	4.13e-06	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	4.09e-06	0.000102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	4.08e-06	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	4.06e-06	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	3.98e-06	9.89e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	3.97e-06	9.87e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	3.85e-06	9.57e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	3.84e-06	9.55e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3.76e-06	9.34e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3.75e-06	9.31e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	3.66e-06	9.1e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	3.56e-06	8.85e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	3.47e-06	8.62e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	3.44e-06	8.54e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	3.43e-06	8.52e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	3.28e-06	8.16e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	3.19e-06	7.93e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	3.19e-06	7.91e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.95e-06	7.33e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.71e-06	6.73e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.62e-06	6.51e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.51e-06	6.23e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.4e-06	5.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.21e-06	5.5e-05	CbGpPWpGaD
